AT&T will experiment with digital-only telephone service in towns in Florida and Alabama in a project that accommodates medical device-related data and services.
MPI Research and its CRO partners are a couple months away from cutting the ribbon on their imaging-focused collaboration, and now the three have installed the particle accelerator they say they'll need to stand out among other drug researchers.
Sequenom's noninvasive MaterniT21 Plus prenatal test is a major growth engine. And the California diagnostics company said it made strides toward a better financial situation in 2013 as a result. Executives bet they can return to break-even/positive cash flow status by the end of 2014 based on the test's continued rollout.
Durham, NC's Scynexis is queuing up for a $55 million IPO, looking to ride the wave of biotech bullishness and raise cash for its in-development anti-infective.
Celgene's roving band of dealmakers has selected San Diego-based Abide Therapeutics for its latest option package, taking an equity stake in the biotech as it settles into a front row seat on its progress regarding a broad R&D front and gaining first dibs on Abide's lead program.
A rejuvenated R&D shop has given Bayer a spate of potential blockbusters, and CEO Marijn Dekkers wants to see more where that came from. The German drugmaker is planning to substantially increase its research budget over the next three years and set aside a boatload of cash for M&A.
After largely abandoning the field back in 1999, Roche is diving back into antibiotics, teaming up with Cambridge, U.K.'s Discuva to discover and develop new treatments for deadly infections using the biotech's novel platform.
A research team published in Nature 's open-access journal Scientific Reports a proof-of-concept study for a drug delivery system using a tattoo to treat cutaneous leishmaniasis, a potentially deadly skin disease spread by bites from sandflies.
Researchers have developed artificial muscles from fibers found in fishing line and sewing thread, according to a study published in the journal Science.
Valeant CEO Michael Pearson has never been a fan of drug R&D. Openly caustic in the past about the risk involved in drug research, Valeant's chief executive has largely steered clear of developing a pipeline, focusing instead on a clear strategy involving the rapid acquisition of marketed drugs.